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Abstract
Tumour recurrence post chemotherapy is an established clinical problem and many cancer types
are often observed to be increasingly drug resistant subsequent to chemotherapy treatments. Drug
resistance in cancer is a multipart phenomenon which can be derived from several origins and in many
cases it has been observed that cancer cells have the ability to possess, acquire and communicate drug
resistant traits.
Here, an in silico framework is developed in order to study drug resistance and drug response
in cancer cell populations exhibiting various drug resistant features. The framework is based on an
on-lattice hybrid multiscale mathematical model and is equipped to simulate multiple mechanisms
on different scales that contribute towards chemotherapeutic drug resistance in cancer. This study
demonstrates how drug resistant tumour features may depend on the interplay amongst intracellular,
extracelluar and intercellular factors. On a cellular level, drug resistant cell phenotypes are here
derived from inheritance or mutations that are spontaneous, drug-induced or communicated via ex-
osomes. Furthermore intratumoural heterogeneity and spatio-temporal drug dynamics heavily influ-
ences drug delivery and the development of drug resistant cancer cell subpopulations. Chemotherapy
treatment strategies are here optimised for various in silico tumour scenarios and treatment objec-
tives. We demonstrate that optimal chemotherapy treatment strategies drastically depend on which
drug resistant mechanisms are activated, and that furthermore suboptimal chemotherapy adminis-
tration may promote drug resistance.
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1 Introduction
Chemotherapy is one of the major anticancer therapies, it is widely used both by itself and as part of
multimodality treatment strategies. In most cases chemotherapy is effective, however the existence, or
the development, of chemotherapeutic drug resistance in tumours continues to be a major problem in
chemotherapeutic treatments, often leading to tumour recurrence post treatment [1, 18, 24, 35, 40, 42, 60].
Clinical and experimental observations suggest that cancers are often increasingly drug resistant subse-
quent to chemotherapy exposure [43, 57, 60, 73] and moreover cancer cells have the ability to posses,
acquire and communicate drug resistant traits, enabling them to survive in the presence of chemother-
apeutic drugs [35]. The existence of drug resistant phenotypes in cancer cell populations significantly
impacts the efficacy and successfulness of chemotherapy [17, 66, 76].
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The emergence of drug resistant cancer cells in tumours results in multiple subpopulations comprising
drug sensitive (S) and drug resistant (DR) cells [17]. Furthermore cancer cell populations may evolve
according to Darwinian principles [68] and cells that acquire drug resistance during chemotherapy have
been observed to be increasingly metastatic [43], consequently DR subpopulations can reach significant
proportions despite initially accounting only for a small fraction of some cancer cell population [35]. S
and DR subpopulations that coexist synergistically compete for resources such as space and nutrients
[39, 68], this competition influences the tumour environment and yields intratumoural heterogeneity. In
clinical cases where tumour eradication is implausible, chronic control treatments can be proposed in
which tumours are continuously managed and prohibited from reaching lethal proportions [25, 35, 39],
long-term chemotherapy treatments are however linked to high frequency drug resistance [41, 63]. Since
DR subpopulations are more fit than S subpopulations to survive in the presence of drugs, repeated
or prolonged chemotherapy administration may amplify this fitness differentiation. Indeed Duan et al.
[17] performed in vitro and in vivo experiments to conclude that in absence of drugs, sensitive cells are
more fit than drug resistant cells and conversely, in presence of drugs DR subpopulations dominate as S
subpopulations are reduced [17]. Thus drug resistant cells may thrive in micro-environments containing
chemotherapeutic drugs, and a large DR subpopulation may result in disease recurrence post chemother-
apy [64]. Ensuring that the DR subpopulation does not dominate the S subpopulation is of importance
as such an outcome would render the tumour uncontrollable by chemotherapy [39]. This suggests that
deliberately maintaining a subpopulation of drug sensitive cells may constitute a strategic countermea-
sure in tumour control schemes [46]. Duan et al. investigated the plausibility of this proposed strategy
in vivo by comparing two cell populations exposed to chemotherapeutic drugs [17]. The first of these cell
populations comprised drug resistant cells only, and the second population contained a combination of
both drug resistant and sensitive cells. Their study confirmed that the second, combined, cell population
was controllable by chemotherapy for a longer time period than the first, drug resistant, cell population
[17].
Drug resistance is a multipart phenomenon which can be derived from several origins, in fact a cancer
cell or tumour may express drug resistance in various ways [35, 46, 61]. Drug resistance may arise due to
micro-environmental or intrinsic cell factors [19] and cells can acquire drug resistance by for example am-
plifying drug target molecules, activating DNA-repair, inducing drug transporters or altering their drug
metabolism [61]. Phenotypical variations in cells, such as drug resistance, can be inherited or acquired
and further, cells may be resistant to one specific drug or to multiple drugs, the latter phenomenon is
known as multidrug resistance (MDR) [33, 35, 41, 68]. Early work performed by Luria and Delbru¨ck on
bacteria indicated that virus resistant mutations occur independently of the virus itself, thus indicating
the existence of primary virus resistance [37]. These findings have since been adapted to oncology [18, 35],
and primary drug resistance, that is drug resistance that occurs independently of the drug presence, is
an accepted phenomenon arising from cell mutations. However, drug presence has been demonstrated
to speed up the development of DR subpopulations [71] and cancer cells may acquire drug resistance by
altering their genetic or epigenetic structure in order to evade drug effects [18]. Such alterations are in-
duced by drug presence and may include dislodging drug receptors or overexpressing and modifying target
molecules [18]. Heat shock proteins (Hsps) are molecular chaperones, continuously present in eukaryotic
cells, yielding cytoprotective cell effects [29, 43]. Via their chaperoning actions they enable cells, both
healthy and cancerous, to adapt to extracellular variations and maintain homeostasis whilst subjected to
external stresses such as, maybe most importantly, hyperthermia but also hypoxia and anoxia, toxins and
the presence of harmful chemical agents such as chemotherapeutic drugs [29, 43, 62, 73]. In healthy cells,
the upregulation of Hsps can protect cells from for example high temperatures [43], however in cancerous
cells Hsp upregulation may protect cells from drug effects [43, 73], thus enabling cells to survive under
otherwise lethal conditions [29]. By extension Hsps have been linked to resistance to chemotherapeutic
drugs [43] such as cisplatin, doxorubicin [73] and bortezomib [62].
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Typical chemotherapy drugs target cells in active cell cycle phases, thus quiescent cells parry drug
effects [40] and similarly slow-cycling cells are intrinsically more drug resistant than fast cycling cells
[13, 64] as they are more likely to evade drug attacks. Slow-cycling cells have been linked to cancer stem
cell-like (CSC-like) cells [40], they are important drivers for tumours due to their increased drug-survival
rate and ability to serve as reserve stem cells [13, 64]. CSC-like cells have been depicted to display various
traits including being slow-cycling, migratory and non-adhesive [1]. Rizzo et al. [57] demonstrated in
vivo in mouse tails that a subpopulation of CSC-like cells indeed may benefit from drug presence when
competing for resources with other cell populations. Thus slow-cycling cells have been identified to re-
inforce tumours, hence to eradicate cancer cell populations containing a subpopulation of slow-cycling
cells it is crucial to target both slow-cycling and fast-cycling cells [13]. Intracellular communication is
vital for multicellular organisms and cells may communicate with each other using chemical signalling,
direct physical contact or, as discussed here, sending and receiving exosomes [63, 78]. Out of these
listed information mediators, exosomes are of particular interest as they are detectable, cell type-specific
and able to travel long distances [63, 78]. This implies that they could potentially constitute therapeu-
tic targets or biomarkers and thus be used to impede or signal cancer [63, 78]. Exosomes constitute
subcellular ”molecule-parcels” that cells may utilise to dispose of non-essential materials [78], however
perhaps more interestingly, they also facilitate long-distance intercellular communication by transporting
information from sender cells to recipient cells [14, 30, 63]. These molecule-parcels contain biomolecules
such as proteins, mRNA and DNA which may provide recipient cells with information that can be used
to alter phenotypical attributes, in order to increase fitness [78]. Exosomes are a type of extracellular
vesicle (EV) [11] and recent studies have identified EVs as key players in cancer development as they
can influence tumour growth and metastasis by communicating oncogenic information [78]. EVs have
also been assumed to be a part of the process that converts non-malicious cells into cancerous, and of
optimising the balance between CSCs and non-CSCs [78]. Thus in response to chemotherapeutic drugs,
cancer cells may not only develop individual drug resistance, but furthermore they may render other cells
drug resistant by secreting exosomes to communicate and share drug resistant traits [11]. Exosomes may
induce both destructive and protective cell responses, in fact the role of EVs depends on the regarded
scenario [20]. In this study pathogenic exosomes only are modelled.
Mathematical models of tumour growth and treatment response may further cancer research by con-
tributing insight into tumour dynamics, elucidating and validating clinically and experimentally recog-
nised phenomena and guiding in vitro and in vivo experiments [25, 27, 35, 39, 66, 68]. Computational
approaches to simulate biological systems are an important part of theoretical biology and may provide
insights into biological phenomena [23]. In silico experiments have the advantage of cheaply being able
to reproduce biological systems that span long time periods faster than real-time [68] and they can be
used to find optimal treatment scheduling [32, 74]. Various such mathematical models of tumour growth,
treatment response and drug resistance have previously been proposed [7, 35, 36, 45, 48, 54, 59, 65].
Roose et al. presented a comprehensive review of models of avascular tumour growth [59] and Lavi et
al. compiled an extensive report discussing previous work on mathematical models of drug resistance
in cancer [35]. To name a few such models, Monro et al. [39] presented a continuum model in which
tumour growth follows Gompertzian dynamics and drug resistant mutations occur proportionately to
the tumour growth rate, in accordance with Luria Delbru¨ck models. They concluded that increased
drug administration may in fact reduce the survival length of a patient. Sun et al. [66] investigated
therapy-induced drug resistance using a set of stochastic differential equations, they highlighted micro-
environmental contributions to drug resistance. Powathil et al. [54] used the Compucell3D framework
[67] to investigate two coexisting subpopulations, specifically one fast-cycling and one slow-cycling, in the
presence of drugs to demonstrate intrinsic drug resistance of slow-cycling cells. There currently exists
a number of hybrid discrete-continuum mathematical models that account for the multiscale nature of
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cancer [55], these models can be used to study tumour behaviour in response to multimodality treatment
schemes [3, 4, 21, 28, 31, 47, 56]. Several modelling attempts have been made to address the multiscale
aspects of cell growth by incorporating details such as vascular dynamics, oxygen transport, hypoxia,
cell division and other intracellular features in order to study tumour dynamics and treatment response
[38, 44, 49, 77]. Recently, Powathil et al. [51, 52] developed a hybrid multiscale cellular automaton,
integrating cell cycle dynamics and oxygen distribution to study cell cycle-based chemotherapy delivery
in combination with radiation therapy. As an important step towards personalised medicine, Caraguel et
al. [9] managed to create virtual clones of in vivo tumours in mice using multiscale hybrid modelling. The
tumour growth of various mouse tumours successfully agreed with the tumour growth of their respective
virtual clones. Details of other multiscale cancer models are available in a review by Deisboeck et al. [15].
In the present in silico study, we propose a hybrid multiscale mathematical model that incorporates
multiple types of drug resistance. in silico experiments are performed in order to study chemotherapeutic
drug response in heterogeneous cancer cell populations hosting various types of drug resistant phenotypes
pre, peri and post chemotherapy.
2 Model and in silico Framework
Following previous work by Powathil et al. [52], tumour growth and drug dynamics are modelled with
a cellular automaton (CA). An overview of the relevant multiscale hybrid modelling techniques can be
found in a later paper by Powathil et al. [53]. In this study, we expand on this model to incorporate
multiple types of mechanisms that elicit drug resistance in cancer cells. Specifically, the CA used in
this study can be categorised as a hybrid multiscale on-lattice model [55], incorporating a non-uniform
micro-environment, extracellular dynamics, intracellular dynamics, intercellular dynamics and various
categories of drug resistance regarded on a cellular resolution. The CA model uses mechanistic par-
tial differential equations (PDEs), ordinary differential equations (ODEs) extracted from a regulatory
molecular network, as well as stochasticity and phenomenological rules formulated by observations from
biological experiments and clinical reports. An overview of the model schematics are illustrated in Figure
1 and details are provided throughout this section. The CA extends in two spatial dimensions, specifi-
cally a 100 by 100 square grid is utilised to simulate a physical tissue slab of (2 mm)2. This agrees with
biological dimensions and each grid point is occupied by a cancer cell, a blood vessel cross section or
extracellular matrix [52]. At the start of the in silico experiment one initial cancer cell is planted at the
centre of the grid, over time this cell divides to give rise to a population of cancer cells and eventually
chemotherapeutic drugs are applied to the system. Blood vessels are non-equidistantly scattered across
the grid, they are assumed stationary and perpendicular to the two-dimensional tissue slab. Thus blood
vessel cross sections live on the grid, where they act as source points for oxygen and drugs.
2.1 Intratumoural heterogeneity
Tumours are dynamic and should therefore be modelled as such [61], they are also heterogeneous and
may constitute multiple distinguishable subpopulations [61, 68]. Intratumoural heterogeneity has been
observed to promote drug resistance [61, 66] and hinder successful tumour prediction, thus by exten-
sion intratumoural heterogeneity complicates intelligent chemotherapy administration [68]. A tumour
can express intratumoural heterogeneity in various ways and on multiple scales. For example nutrient
concentrations, cell cycle dynamics and drug resistant traits may vary amongst cells in a tumour [66, 68].
Phenotypical attributes, such as drug resistant traits, may be acquired or inherited [68] and moreover
stochasticity occurs naturally in biological processes. Hence various phenotypical subpopulations may
arise in a cancer cell population, even if the population originates from one single cell [61]. To effectively
treat tumours one should thus account for intratumoural heterogeneity, including the potential uprising
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Intracellular dynam
ics
Figure 1: A schematic representation of the multiscale hybrid mathematical model used in this study.
The model integrates extracellular, intracellular and intercellular dynamics. This is an on-lattice model
and a lattice point may be occupied by a sensitive (S) or drug resistant (DR) cancer cell shown in black,
a blood vessel cross-section or extracellular matrix. Various categories of drug resistance regarded on a
cellular resolution are incorporated in the model, these categories are marked in red and listed in Table
1.
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of drug resistant subpopulations [68]. Our model accounts for intratumoural heterogeneity on various
scales, details are provided in the following subsections. On a cellular level, each cell has an individ-
ual cell cycle length and individual drug resistant traits. On an extracellular level, the spatio-temporal
micro-envrironment is highly dynamic, each cell has its own neighbours and moreover the blood vessels
are non-equidistantly placed that oxygen and drug concentrations vary asymmetrically across the grid.
2.1.1 Intracellular dynamics
The cell cycle mechanism can be partitioned into four sequential main phases, namely the gap 1 (G1),
synthesis (Syn), gap 2 (G2) and mitosis (M) phase. In the synthesis phase, the DNA duplicates and in
the mitoses phase chromosome segregation and cell division occur [26]. Between these two phases a cell
requires time to grow and double its protein and organelle mass in order to replicate its DNA and divide,
such intermediate phases are dubbed the gap phases. If some conditions are unfavourable a cell may delay
its reproduction progress by exiting the cell cycle to enter an inactive, quiescent phase (G0) [52]. In the
model, cancer cells are categorised as being in either the G1 phase or in the collective Syn-G2-M phase
of the cell cycle, alternatively cells can exit the cell cycle and enter the quiescent phase G0 [52]. The cell
cycle of each individual cell is governed by a regulatory molecular network described by a system of ODEs
(Equation 1) [52] in which the dependent variables are protein concentrations and cell mass (mass). The
relevant proteins are namely the Cdk-cyclin B complex (CycB), the APC-Cdh1 complex (Cdh1), the
p55cdc-APC complex in its total form (p55cdcT ) and active form (p55cdcA), and finally the Plk1 protein
in its active form (Plk1). Details of protein functions and dynamics are provided in the Supplementary
Material. The Cyclin B value is used as a marker to determine which state of the cell cycle that the cell
is in, and by extension when cell division occurs as this happens when the cell exits Syn-G2-M phase to
enter the G1 phase. Specifically, cell division occurs when the threshold value [CycB]thr = 0.1 is crossed
from above [52, 70]. When cell division occurs at time step tcd in the model, a daughter cell is placed
on a grid point in the spherical neighbourhood of the parental cell, located in point xparent. At cell
division the mass of the parent cell is halved so that [mass](xparent, tcd) =
1
2 · [mass](xparent, tcd − 1)
[70]. Grid points in lower order neighbourhoods are prioritised in this process, however up to third-level
neighbourhoods are regarded. Each cell may divide until there is no unoccupied grid point on which to
place a daughter cell, when this occurs a cell enters the quiescent phase G0. A cell may however re-enter
the cell cycle if its neighbourhood is freed up and space is made available. Whilst in a quiescent phase
cells are assumed to be drug immune in our model, this is because classical chemotherapy drugs target
molecules that are overexpressed in specific cell cycle phases, for example the drug cisplatin affects the
G1 phase of the cell cycle [52, 72]. The ODE that regulates the cell cycle reads
d[CycB]
dt
=k1 − (k′2 + k′′2 [Cdh1] + [p27/p21][HIF ])[CycB], (1a)
d[Cdh1]
dt
=
(k′3 + k
′′
3 [p55cdcA])(1− [Cdh1])
J3 + 1− [Cdh1] −
k4[mass][CycB][Cdh1]
J4 + [Cdh1]
, (1b)
d[p55cdcT ]
dt
=k′5 + k
′′
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([CycB][mass])n
Jn5 + ([CycB][mass])
n
− k6[p55cdcT ], (1c)
d[p55cdcA]
dt
=
k7[Plk1]([p55cdcT ]− [p55cdcA])
J7 + [p55cdcT ]− [p55cdcA] −
k8[Mad][p55cdcA]
J8 + [p55cdcA]
− k6[p55cdcA], (1d)
d[Plk1]
dt
=k9[mass][CycB](1− [Plk1])− k10[Plk1], (1e)
d[mass]
dt
=µ[mass](1− [mass]
m∗
), (1f)
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where the coefficient µ is individual to each cell and depicts cell growth rate, it takes a randomised
value within an allowed range to account for heterogeneous cell cycle lengths amongst cells [52]. The
variable [HIF ] corresponds to the hypoxia inducible transcription factor-1 (HIF-1) pathway, in the model
this factor is activated if the cell is classified as hypoxic [52] so that [HIF ] = 1 in hypoxic cells and
[HIF ] = 0 in normoxic and hyperoxic cells. Oxygen distribution, and by extension hypoxia, is governed
by an extracellular PDE, hence extracellular and intracellular dynamics are here integrated. Cellular
accumulation of the HIF-1 α protein is furthermore associated with chemotherapeutic drug resistance
[6]. Equation parameters are listed in the Supplementary Material.
2.1.2 Extracellular dynamics
Extracellular dynamics is modelled using mechanistic PDEs describing oxygen and drug distribution.
Oxygen is continuously produced at each time step on the blood vessels cross sections from which it is
distributed across the grid according to the following diffusion-reaction equation [52],
∂K(x, t)
∂t
= ∇ · (Dk(x, t)∇K(x, t)) + rk(x, t)m(x)− φkK(x, t)cell(x, t), (2)
where K(x, t) denotes oxygen concentration in location x at time t, Dk(x, t) is the oxygen diffusion
coefficient, rk(x, t) is the oxygen production rate and φk is the oxygen consumption rate. The variables
m(x) and cell(x, t) are binary so that m(x) = 1 if there is a blood vessel in location x and m(x) = 0
otherwise. Likewise cell(x, t) = 1 if there is a cell in location x at time t and cell(x, t) = 0 otherwise. No-
flux boundary conditions are applied, such boundary conditions coupled with the oxygen production at
each time step will cause the total oxygen in the system to fluctuate over time. Thus in accordance with
previous work by Powathil et al. [50], the absolute hypoxic threshold value will be different at each time
step in the simulation, whilst the relative hypoxic threshold value will remain the same over time. This
approach yields a spatial oxygen distribution at each time step which can be used to evaluate hypoxia.
Physically, a cell is here classified as being hypoxic if its partial pressure of oxygen (pO2) is 10 mm Hg or
less [10, 52]. Following Powathil et al. [52], a grid point in the implementation is defined to be hypoxic if
it has a relative oxygen concentration of less than 0.1, where an oxygen concentration of 1 is normalised
at the grid point with the highest oxygen concentration on the grid. Oxygen diffuses slower over grid
points occupied by cancer cells than elsewhere and sufficiently high oxygen concentrations promote rapid
cell proliferation, whilst hypoxia hinders cell cycle advancement. These hypoxic effects are incorporated
in the model via the [HIF ] parameter occurring in Equation 1 [52]. Chemotherapy drugs are similarly
administered via blood vessel cross sections, however drugs are instantaneously produced at one single
time step per drug administration. Drugs diffuse according to Equation 3,
∂C (x, t)
∂t
= ∇ · (Dc(x, t)∇C (x, t)) + rc(x, t)m(x)− φcC (x, t)cell(x, t)− ηcC (x, t), (3)
using no-flux boundary conditions. Here C (x, t) denotes drug concentration in location x at time t,
Dc(x, t) is the drug diffusion coefficient, rc(x, t) is the drug production rate, φc is the drug consumption
rate and ηc is the drug decay rate. Chemotherapy drugs diffuse faster across extracellular matrix than
inside the tumour [52]. Provided that the cell is in the drug-targeted cell cycle phase and that the cell
is not explicitly drug resistant, a cell in location x at time t is killed if the drug concentration C (x, t) is
such that C (x, t) ≥ κ, where κ is the lethal threshold drug concentration. When a cell dies, its grid point
x becomes empty end the drug concentration C (x, t) is halved, simulating drug binding by the cell. This
drug binding compensates for the fact that the consumption term is omitted in Equation 3 as φc is set
to be 0, as is described in the Supplementary Material. Parameters occurring in the PDEs are also listed
in the Supplementary Material.
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2.2 Drug resistance
In this study, drug resistance is regarded on a cellular resolution, thus subcellular mechanics are simplified
and drug resistance is categorised into cellular-level categories as illustrated in Figure 2. In the model
drug resistance is firstly categorised as being either explicit or implicit. Explicit drug resistance occurs
when a cell possesses any subcellular trait that directly protects it from drug effects, rendering it immune
to some drug. Conversely, a cell displays implicit drug resistance when it is shielded from drug impact
due to some indirect reason such as being slow-cycling or spatially located in a region of low drug
concentration. Explicit drug resistant traits can be induced or inherited [34, 58] and also, cells may
perform phenotypical alterations in response to intercellular interactions [61]. Therefore we here categorise
drug resistance as being induced, primary or communicated. Induced drug resistance is activated in cells
as a defensive response to drug presence whilst primary drug resistance is caused by cell mutations
occurring independently of drugs [34, 58]. Cancer cells in which drug resistance has been induced may
communicate and spread their drug resistant traits to other cancer cells via intracellular communication
(ICC) in an effort to secure species survival [11, 63, 78]. Using hybrid modelling, the various categories
of drug resistance are here modelled in different ways in order to easily reproduce biological phenomena
in a way that is consistent with available clinical and experimental observations and data. In our model,
drug resistance obeys rules formulated from previous findings from in vitro and in vivo results. Also
incorporated are stochastic methods, as stochasticity occurs naturally in biological processes and may
generate different cell phenotypes [61]. For all categories of phenotypical drug resistance, it is assumed
that once a cell has established a drug resistant trait, its offspring will inherit that trait. This is in
accordance with evolutionary Darwinian principles, as DR subpopulations are more fit to survive in drug
presence than are S subpopulations [22]. Furthermore, the micro-environment influences drug transport
across the tumour and impeded drug delivery by poor diffusion is indeed one of the primary reasons for
treatment failure [35]. Thus drug efficacy and cytotoxic cell death is affected by the micro-environment,
since drugs may not reach target cells. This may occur if the drug diffusion is impeded by dense population
regions, or if the target cells are spatially located far away from drug source points, here blood vessels.
To study how a heterogeneous micro-environment impacts drug resistance and drug response, blood
vessels are non-equidistantly located across the in silico domain. Moreover, the speed of molecules such
as oxygen, drugs and exosomes, depends on the medium that the molecules in question are traversing
[52, 63]. This section provides information regarding the modelling of various drug resistant categories.
Numerical values of the parameters introduced in this section are listed in the Supplementary Material,
along with schematic representations of algorithms used in the model and a sensitivity investigation of
critical parameters which demonstrates that our results are robust in regards to these parameters. Thus
our qualitative findings, concerning drug response in cancer cell populations hosting various types of drug
resistance, hold for variations of the chosen parameters.
2.2.1 Primary drug resistance
Cells display primary drug resistance independently of drug presence, thus primary drug resistance may
precede chemotherapy [35, 37, 58]. The in silico setup in our study is analogous to Luria and Delbru¨ck’s
[37] in vitro experiment, however here bacteria and virus have been exchanged for cancer cells and
chemotherapy drugs respectively. Luria and Delbru¨ck [37] stated that there was a probability per unit
time that a sensitive cell would mutate into a, here drug, resistant phenotype. Thus in accordance with
Luria and Delbru¨ck models [37], primary explicit drug resistance is here modelled by stochastic cell
mutations occurring at cell division. More specifically the chance of mutation is given by the mutation
rate αpri, which corresponds to the probability of mutation per cell cycle. The parameter αpri is assumed
to be small, so that drug resistant mutations are rare and moreover the probability that a mutated cell
will revert back to a sensitive state is negligible and set to zero [37]. Hence in our model each daughter
cell that is produced has a chance αpri of being explicitly drug resistance before being placed on the grid.
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Figure 2: Classification of drug resistance categories occurring in the model. Drug resistance may be
independent of drug presence (orange labels), induced as a consequence of drug presence (purple labels),
or either (orange and purple labels). Cell acquisition of any DR phenotypical trait (top half) is here
modelled as irreversible and inheritable by any future daughter cells to the cell in question.
2.2.2 Induced drug resistance
Drug presence has been demonstrated to speed up the development of DR subpopulations in cancers [71]
and multiple studies have shown that cancer cells display altered epigenetic features following chemother-
apy [34]. Cancer cells may become drug resistant after exposure to chemotherapy, the underlying cause of
such induced drug resistance is assumed multifactorial [58]. Factors that may contribute to induced drug
resistance include decreased apoptotic response, increased DNA-repair post drug-mediated damage, cell
cycle alterations and reduced drug accumulation [58]. These factors may work concurrently and jointly
towards establishing drug resistance in cells [58]. Hsps aid signalling pathways promoting cell growth and
sustainability [43], and may induce anti-apoctic cancer cell properties [29]. Three members of the Hsp
family that have been under scrutiny are namely Hsp27, Hsp70 and Hsp90, which have all been linked to
promoting breast cancer tumours [43] and shown in vivo to contribute towards chemotherapeutic drug
resistance [73]. In cancer cells, Hsps are plentiful and moreover administration of chemotherapeutic drugs
has been observed to alter Hsp expression and increase Hsp activity [29]. Hsps may reside in both the
cytoplasm and the cell nucleus, Vargas-Roig et al. demonstrated in vivo that chemotherapy drugs may
modify the proportion of Hsps in different cell compartments [73], in fact drug administration resulted
in increased nuclear expression, and decreased cytoplasmic expression of Hsp27 and Hsp70 [73]. Hsp27
promotes cell migration and differentiation in vivo [43] and elevated Hsp27 levels have been correlated
to doxorubicon resistance and correspond to high tumorigenicity whilst low Hsp27 levels suppress tu-
mour functions such as angiogenesis and proliferation of endothelial cells [43]. Hsp70 is linked to tumour
growth and yields anti-apoptotic effect in tumours [43] and in breast cancer cells, a high propotion of
nuclear Hsp70 is correlated to drug resistance [73]. Hsp90 is associated with regulating the cell cycle and
controlling metastasis and proliferation [43] and high Hsp90 levels are linked to decreased survival rates
in breast cancer patients [43]. Inhibiting Hsp27, Hsp70, Hsp90 has been hypothesised as part of future
treatment plans [29, 62] and moreover Hsp70 has been suggested as a factor to prognostically evaluate
the risk of disease recurrence [43]. The heat shock factor 1 protein (HSF1) regulates Hsps [62, 75], and
HSF1 overexpression is linked to poor prognosis in breast, lung and colon cancers, an increase in intratu-
moural cancer stem cells proportions and chemotherapeutic drug resistance [75]. Specifically, cells with
high HSF1 levels have displayed increased paclitaxel resistance [75]. Although cellular Hsp expression
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and activity have been linked to anti-cancer drug resistance, the details of these mechanisms are yet
to be elucidated [73]. Thus in the mathematical model discussed in this paper, details concerning such
underlying mechanisms of acquired drug resistance are omitted and we simply recognise the fact that if
a cell has been exposed non-lethal drug levels for a certain amount of time, it can develop resistance to
that drug. Furthermore, clinically, cancers are usually treated with combination therapies which makes
it difficult to deduce rigorous information regarding how induced drug resistance is developed in cells as a
response to one particular drug [69]. Due to this multifactorial nature of induced drug resistance, which
involves various subcellular alterations occurring in response to drug presence in the micro-environment,
in the model a cell obtains induced explicit drug resistance once it has been exposed to a high enough drug
concentration for a sufficiently long time. Thus if a cell has experienced a minimum drug concentration
χind for τ time units, drug resistance is induced in the cell.
2.2.3 Communicated drug resistance via exosomes
Srinivasan et al. [63] investigated exosome kinetics in lymphatic flow in vitro and in vivo using near
infrared imaging. In the in vitro study, they found that planted exosomes from the HEY cell line, being
spherical with a diameter of around 70 nm, travelled more effectively than size and density matched
beads across lymphatic endothelial cells (LECs). This indicates that exosomes travel purposefully as
opposed to randomly. Srinivasan et al. [63] reported an effective permeability for exosomes across the
lymphatic endothelium in the order of 0.2 µm/s and moreover exosomes were transported twice as fast
across areas with cells compared to areas with no cells. Exosomes were observed to move rapidly in
vivo, indeed they travelled 10 cm in a mouse tail within 2 minutes [63]. Studies also show that there is
a correlation between the micro-environment and exosome activity, as exosome secretion and uptake is
promoted in low-pH regions [78]. Further, hypoxic regions are associated with drug resistance [2] which
is partly explained by elevated exosome secretion in such regions [11]. Here, exosomes are modelled
using phenomenological rules formulated from experimental observations, incorporating stochasticity.
Exosomes are modelled as discrete ”molecule parcels”. Once per cell cycle each cell that has acquired
drug or exosome induced drug resistance has a chance αex of producing and secreting such a molecule
parcel which is sent off in a random direction. The first sensitive cell that the exosome hits is dubbed
the recipient cell, upon receiving the exosome the recipient consumes the parcel to gain drug resistance.
Exosome production and uptake times are incorporated in the travel time and thus modelled as instant,
using data from Srinivasan et al. [63] we choose a propagation speed of 0.2 µm/s which is equivalent to
1 grid point (20 µm) per 100 s when travelling across cells, and half of this speed when travelling across
extracellular matrix. The chance of exosome production αex is significantly higher in hypoxic regions in
order to account for increased exosome activity in such regions [11].
2.2.4 Cell cycle mediated drug resistance by slow-cycling cells
Slow-cycling cells are distinguishable in vitro [13] and Srinivasan et al. [64] demonstrated that fast and
slow-cycling cells may coexist in a tumour. Many chemotherapeutic drugs, such as cisplatin, attack
only cells in a certain phase of the cell cycle by targeting proteins overexpressed in the corresponding
phase, leaving other cells unaffected [52, 72]. Since the half-life times of common chemotherapy drugs are
significantly shorter than the average cell cycle length of standard eukaryotic cells [52], slow-cycling cells
are implicitly more resistant to chemotherapy as they are likely to evade drug impact whilst being in a
prolonged untargeted cell cycle phase. Consequently, if there exists a subpopulation of slow-cycling cells
in a tumour, this subpopulation is more likely to survive chemotherapy and proliferate post treatment,
despite having a slower production rate. Such a slow-cycling subpopulation may comprise CSC-like cells,
as slow-cycling cells have been linked to cancer stem cells [40], which in turn have been conferred with
reduced sensitivity to chemotherapeutic drugs [75]. Previous research indicates that cancer cells may
obtain stem-cell like traits [16], in fact non-stem cancer cells may convert into CSC-like cells seemingly
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spontaneously, as demonstrated in vivo by Chaffer et al. [12]. Micro-environmental factors, such as
oxygen supply, may influence such conversions however here cell conversion into a slow-cycling state is
modelled as independent of the micro-environment. The [HIF] parameter, occurring in Equation 1, which
is switched on in hypoxic cells only does however increase the cell cycle length of all cells, fast-cycling and
slow-cycling, and thus in the model oxygen levels effect cell-cycle lengths. Slow-cycling cells are multidrug
resistant as they are resistant to any drug that targets only a subset of cell cycle phases. In the model
we assume that slow-cycling conversion occurs spontaneously, independently of drug presence. More
specifically, once per cell cycle there is a chance αSC that a sensitive, fast-cycling cell will spontaneously
convert into a slow-cycling state. Here slow-cycling cells are assumed to have a cell cycle length that is
roughly twice as long as a sensitive cell [54]. The chance of conversion from a slow-cycling, implicitly drug
resistant state back into a fast-cycling state is assumed negligible in accordance with previously discussed
Luria Delbru¨ck models [37] and Darwinian principles and thus set to zero. Furthermore the in silico
experiment spans 700 hours only, and the chance that a cell converts and re-convert is assumed negligible
in the model. Once a cell is randomly selected to convert into a slow-cycling state, the individual growth
rate factor µ of the regarded cell, occurring in Equation 1, is updated in order to achieve slower cell-cycle
progression and by extension a longer cell-cycle length. Daughter cells to slow-cycling cells are assigned
appropriate growth rates associated with slow-cycling cells at creation. Permitted growth rates for both
sensitive fast-cycling cells and slow-cycling cells are listed in the Supplementary Material.
2.3 Implementation
The CA is implemented in C/C++ using a high performance computational framework. Ordinary differ-
ential equations are solved using a fourth order Runge-Kutta method and partial differential equations
are solved using explicit finite difference schemes. Prior to commencing the in silico experiment, the
micro-environment is implemented and thus blood vessel cross sections are scattered in a non-equidistant
fashion across the grid, this is in order to emphasise and study the effects of spatio-temporal oxygen and
drug heterogeneity. One initial cancer cell is then planted at the centre of the grid, from this originat-
ing cell the cancer cell population will grow. Tumour growth is simulated over 700 hours, where it has
been concluded that 700 hours is a sufficiently long simulation time to study the drug resistance and
drug response in the system. Here, a time step size ∆t = 10−4 hours, is used in accordance with the
appropriate nondimensionalisation of the oxygen parameters occurring in Equation 2 [52]. Cisplatin, a
chemotherapy drug which here is modelled to attack G1 cells only, is administered in two instances at
500 and 600 hours. For each such instance, drugs are produced on all blood vessels at one single time
step. The total amount of drug produced at one time step, on all blood vessels, corresponds to the drug
dosage, which can be varied to study various cases. Specifically, here the studied drug dosage are: (1)
1C, (2) 2C, (3) 4C or (4) 8C, as listed in Table 2. The dosage 1C is parametrised so that, in the absence
of drug resistant phenotypes amongst the cells, 1C kills half of the total cell population shortly after the
first drug administration at 500 hours. By doubling the drug dosage once, twice or thrice to 2C, 4C or
8C respectively a higher cell kill is achieved. However, the relationship between the drug dosage and the
number of cells killed is not linear, as is further discussed in Section 3.1.1. For the fixed chemotherapy
schedule at 500 and 600 hours, the administered drug dosages are varied and the size of the sensitive and
drug resistant cell subpopulations are computed pre, peri, and post chemotherapy. Cell-maps are pro-
duced in order to display cell population topology over time, these cell-maps are visualised in ParaView
[5]. Five different in silico experiments are here performed, corresponding to five different categories of
drug resistance namely (a) to (e) listed in Table 1. Each experiment is performed 100 times, subsequently
average values and standard deviations are reported. A sensitivity investigation of critical parameters is
performed in order to confirm that our results are robust in regards to small parameter variations, this
is available in the Supplementary Material.
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Label Drug Resistance Category
a No drug resistance (No DR)
b Primary drug resistance (Primary DR)
c Induced drug resistance (Induced DR)
d Induced and, via exosomes, communicated drug resistance (ICC DR)
e Cell cycle mediated drug resistance by spontaneous conversion to slow-cycling cells (SC DR)
Table 1: The labelling of drug resistance categories occurring in the model.
Label Drug dosage
0 0 C (No drug)
1 1 C
2 2 C
3 4 C
4 8 C
Table 2: The labelling of drug dosages used in the implementation. For non-zero drug dosages the
labelling system is such that label ` corresponds to drug dosage 2`−1.
3 Results and Discussion
3.1 Results
In absence of chemotherapeutic drugs, the growth of the DR subpopulation in our in silico experiment
is proportional to the growth of the S subpopulation, as demonstrated by the graphs in Figure 3. This
is in accordance with previous mathematical models and experimental results [35, 37, 39].
3.1.1 No drug resistance
Once chemotherapy is applied to the in silico setup, the cancer cell population decreases in response
to drugs. This is especially clear when no drug resistant phenotypes exist, the cancer cell population
then rapidly reduces after drug administration. However population growth quickly resumes, and the
size of such populations eventually reaches, and surpasses, the pre-chemotherapy population size. This
is evident in graphs (a1) through to (a4) in Figure 4, and especially clear for high chemotherapy dosages
where the size of the cell population cycles between being large immediately before drug administration
and being small directly after drug administration. Rottenberg and Borst [60] demonstrated similar
cyclic behaviour in mouse tails in vivo. Increasing the drug dosage trivially kills more cancer cells,
however tumour topology and spatial heterogeneity significantly affects drug transport. Moreover, due
to intratumoural heterogeneity in regards to the cell cycle, some cells will be shielded from the drug
simply by being in an untargetted cell cycle phase. This multiscale heterogeneity affects the relationship
between drug dosage and drug efficacy, where drug efficacy here corresponds to the number of cells killed
by the drug. Graphs (a1) to (a4) in Figure 4 demonstrate the poor scaling between drug dosage and drug
efficacy. Further, here we define the scaling efficiency  by
i =
ki
k1 ·Ni , (4)
where ki denotes the number of cells killed in experiment i and Ni denotes the dimensionless drug dosage
coefficient used in experiment i. Thus here, i = 1, 2, 3, 4 and respectively Ni = 1, 2, 4, 8. If the relationship
between drug dosage and drug efficacy was linear, doubling the drug dosage would mean doubling the
number of cancer cells killed. In such an ideal case it would hold that i = 1∀i, however this is not the
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(a0)
Figure 3: Growth of the cancer cell population over time in drug absence, showing total population (black
graph), drug sensitive subpopulation (blue graph) and drug resistant subpopulation (red graph) incorpo-
rating drug resistance categories (a0) No DR, (b0) Primary DR and (e0) SC DR. Cases (c0) Induced DR
and (d0) ICC DR are omitted since they produce the same results as (a0) in drug absence. Each graph
shows the average number of cells based on 100 simulations, the standard deviation is demonstrated with
error bars.
case, as illustrated in Figure 5 which shows the scaling efficiency for the first drug administration at 500
hours. Hence in a clinical setting, the harm that may follow increased toxicity from higher drug dosages
may not be worth the modest increase in killed cancer cells. The cell-maps in Figure 6 further highlight
how the spatial heterogeneity affects drug delivery and consequently where the drug concentrations are
high enough for cell kills to occur.
3.1.2 Primary drug resistance
When a cancer cell population expresses primary drug resistance, two subpopulations, comprising sensi-
tive and drug resistant cells, already coexist prior to chemotherapy. Once administered, chemotherapy
eliminates cells belonging to the S subpopulation whilst leaving the DR subpopulation unharmed. Hence
increasing the drug dosage, and consequently killing more sensitive cells, enables the DR subpopulation
to flourish as it gains access to more resources such as space and oxygen. Graphs (b1) through to (b4)
in Figure 4 show that such DR subpopulations indeed benefit from high drug environments. Over all,
our results show that chemotherapeutic treatments yield poor results if there exists a subpopulation of
drug resistant cells prior to commencing treatment, this supports clinical observations depicting that
primary drug resistance gravely reduces the successfulness of chemotherapy and influences the choice of
treatment regime [18]. In our experiment, primary DR subpopulations grows outwards in radial strands
pre chemotherapy, as illustrated in cell-maps (b1) and (b4) in Figure 6. This geometry is explained by
the model, in which primary drug resistant mutations occur at cell division, prior to placing the cell on
the grid. Moreover drug resistant cells produce drug resistant offspring, thus radial strands are formed
as the cancer cell population grows. This DR subpopulation will spread from these strands, which con-
sequently will widen post drug administration. On the other hand, subpopulation S will spread from
regions containing sensitive cells that survived drug effect. Such sensitive survivor cells are clustered in
regions of low drug concentrations, typically located far away from blood vessels and enclosed by other
cancer cells, as drugs travel more slowly over dense population regions.
3.1.3 Induced drug resistance
For simulations incorporating induced drug resistance, the DR subpopulation arises post chemotherapy.
Here drugs diffuse more slowly over cancer cells than over extracellular matrix. Therefore, once the
initial effect of chemotherapy has eliminated the majority of the sensitive cancer cells, and the tumour
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Figure 4: Growth of the cancer cell population over time when drugs are applied at 500 and 600 hours,
showing total population (black graph), drug sensitive subpopulation (blue graph) and drug resistant
subpopulation (red graph). Each row in the figure corresponds to a category of drug resistance (a)
to (e) according to the labelling in Table 1, whilst each column corresponds do a specific drug dosage
varying from low (leftmost column) to high (rightmost column), namely (1) 1C, (2) 2C, (3) 4C and (4)
8C according to the labelling system in Table 2. Each graph shows the average number of cells based on
100 simulations, the standard deviation is demonstrated with error bars.
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Figure 5: The scaling efficiency, demonstrating the relationship between drug dosage and drug efficacy
in terms of number of killed cancer cells. This is for the first drug administration at 500 hours for
experiments (a1) to (a4) according to the labelling in Tables 1 and 2, where no drug resistant phenotypes
are present. Results are based on average values for 100 tests.
has disintegrated into clusters of surviving cancer cells, drug resistant cells are typically located on
boundaries between cancer cells and extracellular matrix, as illustrated in cell-maps (c1) and (c4) in
Figure 7. On these boundaries drug resistance is induced since the cells are exposed to high, but non-
lethal, drug concentrations for a sufficiently long time. From these points of origin the DR subpopulation
spread. By increasing the amount of chemotherapy, the cells that are exposed to this intermediate, high
but non-lethal, drug concentration is reduced. Hence higher chemotherapy dosages do not only kill more
cells overall, but reduces the amount of drug resistant phenotypes, as demonstrated by graphs (c1) to
(c4) in Figure 4, this result applies to a cancer cell population in a confined space.
3.1.4 Communicated drug resistance via exosomes
The effect of ICC is demonstrated by comparing experiment (c) Induced drug resistance, to experiment
(d) Induced and, via exosomes, communicated drug resistance. This can be done by regarding graphs
(c1) to (c4) and (d1) to (d4) in Figure 4 and cell-maps (c1), (c4), (d1), (d4) in Figure 7. These figures
show that the communicative exosome component amplifies the effect of induced drug resistance alone.
The number of oncogenic exosomes produced increases with the number of drug resistant cells. In low
to moderate drug environments, many exosomes are thus produced, as there exists many cells which
have acquired induced DR in accordance with the results in Section 3.1.3. Conversely, in very high
drug regimes fewer cells will survive to acquire induced drug resistance and consequently fewer oncogenic
exosomes will be produced. Exosomes have been hypothesised as possible treatment targets, and our
results indicate that reducing the exosome activity would aid the S subpopulation, as less cells would
convert from sensitive to drug resistant. Here, hypoxic cells secrete more exosomes than do normoxic
cells. This results highlights one of the benefits of targeting hypoxic tumour regions, as doing so may
reduce exosome activity and by extension hinder communicated drug resistance.
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3.1.5 Cell cycle mediated drug resistance by slow-cycling cells
Slow-cycling cells are more likely to evade drug effects, as shown in graphs (e1) to (e4) in Figure 4
where, after each drug attack, the DR slow-cycling subpopulation displays a higher survivor rate. High
chemotherapy dosages increase this effect, and thus benefit the DR subpopulation. Since the conversion
to slow-cycling cells is modelled as spontaneous, implicit drug resistance may precede chemotherapy.
Furthermore this spontaneity means that at every cell cycle, each fast-cycling cell has the same chance
αSC of converting to a slow-cycling state. Thus pre chemotherapy the DR subpopulation will be point-
wise scattered across the cell population, and post chemotherapy the DR subpopulation will spread from
these source points, as illustrated in cell-maps (e1) and (e4) in Figure 7.
3.1.6 Cell-map topology
Each drug resistance category in our model corresponds to a typical cell-map topology and vice-versa,
as shown in Figures 6 and 7. The location of the subpopulations S and DR depends on the category of
drug resistance regarded, as does the location of regions with high cell-kill numbers. These cell-maps are
useful for conveying spatial heterogeneity, which is of importance since intratumoural heterogeneity is
known to heavily influence drug efficiency [52]. Any sensitive cell, or cell cluster, that is surrounded by a
band of other cells will be partly shielded from drug effects, as drugs travel slowly over dense population
regions. Further, any quiescent sensitive cell, or cell cluster, that is surrounded by a band of explicitly
drug resistant cells is eternally safe from drug presence in our in silico setup. This is because such a
sensitive cell, or cell cluster, will never meet the necessary condition to re-enter the cell cycle as this
requires free neighbourhood space. Thus even sensitive cell may be protected from drug effect, this is an
example of location mediated implicit drug resistance.
3.2 Discussion
Our study shows that drug response in cancer cell populations is crucially influenced by the drug resis-
tant phenotypes amongst the cells. in silico we demonstrate that the effect of chemotherapy is heavily
dependent not only on the mere existence of drug resistant cells, but also the type of drug resistance
displayed and micro-environmental factors. Clinically this implies that optimal chemotherapy scheduling
and dosages depend on tumour specific data, including information regarding drug resistance and tumour
environment. Indeed our results show that some types of drug resistant phenotypes thrive in low drug
settings, whilst other flourish in high drug settings.
Before proceeding to discuss optimal drug dosages, one must define what constitutes as ”successful”
chemotherapy. Is the aim perhaps to (i) reduce the cancer cell population as much and quickly as possible
or to (ii) be able to control the tumour long-term using chemotherapy? Case (i) may be relevant when
chemotherapy is used in combinations with other treatments, for example when neoadjuvant chemother-
apy is used prior to radiation treatment or surgery. Conversely, Case (ii) may be applicable when chronic
chemotherapeutic treatment strategies are used, as can be done when it is implausible to completely
eliminate a tumour. In such cases it is vital to suppress any DR subpopulation in order to keep the tu-
mour manageable by chemotherapy. For Case (i), Figure 8 provides the data needed to discuss intelligent
treatment strategy. This diagram trivially shows that high chemotherapy dosages are the most effective
to rapidly eradicate cancer cells. However, what is not shown in our result, but is of clinical importance,
is that high drug dosages are coupled with high toxicity which may be harmful to patients. Moreover our
results show that the relationship between drug dosage and drug efficacy scales poorly, which is worth
considering in a clinical setting. The increase in toxicity following from an increased drug dosage may
not validate the outcome in terms of tumour reduction. In Case (ii) there is a balance, and sometimes a
trade-off, between eliminating sensitive cells and aiding the drug resistant cells. Indeed killing of sensitive
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Figure 6: Cell-maps of the cancer cell populations at times 500 h (immediately before first drug dose), 510
h 600 h (immediately before second drug dose), 610 h and 700 h (end of simulation). Cases incorporating
(a) No DR and (b) Primary DR are shown for drug dosages of (1) 1C and (4) 8C according to the labelling
in Tables 1 and 2. White areas correspond to extracellular matrix.
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Figure 7: Cell-maps of the cancer cell populations at times 500 h (immediately before first drug dose), 510
h 600 h (immediately before second drug dose), 610 h and 700 h (end of simulation). Cases incorporating
(c) Induced DR, (d) ICC DR and (e) SC DR are shown for drug dosages of (1) 1C and (4) 8C according
to the labelling in Tables 1 and 2. White areas correspond to extracellular matrix.
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Figure 8: Diagram of the drug sensitive subpopulation (blue) and the drug resistant subpopulation.
Various types of drug resistance are incorporated namely (a) No DR, (b) Primary DR, (c) Induced DR,
(d) ICC DR, (e) SC DR. Results are shown at times 500 h (immediately before the first drug dose), 510
h, 600 h (immediately before the second drug dose), 610 h and 700 h (end of simulation) for low drug
dosages, (1) 1C, and high drug dosages, (4) 8C according to the labelling in Table 2. Each diagram shows
the average value based on 100 simulations.
cells paves the way for any drug resistant phenotypes. Hence administering low chemotherapy dosages
sometimes constitutes a wiser treatment strategy as it delays the uprising of a drug resistant subpopu-
lation. Evolutionary theory and the interaction between S and DR subpopulations may thus play a role
in designing intelligent treatment strategies. Figure 9 shows the ratio between S and DR subpopulations
at different times. This diagram demonstrates that drug resistant phenotypes that arise independently
of drug presence benefit from high drug dosages. However, in silico, the opposite is true here for drug-
induced drug resistant phenotypes, which prosper in low drug conditions. Ideal chemotherapeutic tumour
treatments would involve rapidly reducing tumour size whilst minimising drug resistance, thus meeting
the requirements of both Cases (i) and (ii). However, our results indicate that when using chemotherapy
only, there is a trade-off between tumour reduction and the suppressing of drug resistant phenotypes in
some cases, thus the objectives of Cases (i) and (ii) may conflict.
The aim of this study is to qualitatively model drug response in cancer cell populations hosting
drug resistant individuals. Drug resistance is here modelled from a collective of biological experiments,
biological theory and clinical observations, and thus does not confer strictly with one cell line or one
experiment. However, the developed in silico framework can be parametrised and calibrated appropriately
for a cell-line specific study (as shown in a recent paper [8]), should relevant biological data become
available in detail. Our in silico framework is equipped to handle various mechanisms concerning drug
resistance, these mechanisms can be appropriately included or excluded in order to study a certain cell-line
or a certain tumour scenario.
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Figure 9: Diagram of the ratio between the drug sensitive subpopulation (blue) and the drug resistant
sub-population. Various types of drug resistance are incorporated namely (a) No DR, (b) Primary DR,
(c) Induced DR, (d) ICC DR, (e) SC DR. Results are shown at times 500 h (immediately before the first
drug dose), 510 h, 600 h (immediately before the second drug dose), 610 h and 700 h (end of simulation)
for low drug dosages, (1) 1C, and high drug dosage, (4) 8C according to the labelling in Table 2. Each
diagram shows the average value based on 100 simulations.
4 Conclusion
Enhanced chemotherapeutic drug resistance post-chemotherapy is an established clinical problem, this
study provides insight into drug resistance and drug response in cancer cell populations on a cellular
resolution. Our results show that, whilst chemotherapy is an effective way to reduce tumours, suboptimal
drug dosages may contribute towards drug resistance and, by extension, tumour reinforcement. Thus, in
accordance with Nietzschean philosophy, chemotherapy that does not kill a tumour may indeed make it
stronger. Generally we found that drug resistance presenting independently of the drug, which thus may
precede chemotherapy, is amplified by high drug dosages. However, drug resistance that is induced by
drug presence is accelerated by low to moderate drug dosages. These findings are pictorially demonstrated
in Figure 10.
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Figure 10: Tumours exposed to chemotherapeutic drugs given in low (top) or high (bottom) dosages,
the latter dosage option kills more cancer cells. One of the tumours (left) expresses drug resistance pre
chemotherapy, the other one (right) does not. Generally in our in silico experiment, drug resistance that
occurs independently of the drug, and thus may precede chemotherapy, is amplified by high drug dosages
(left). Conversely, drug resistance that is induced by drug presence is accelerated by low to moderate
drug dosages (right).
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